GBC AG Covers Marinomed Biotech AG with Buy Recommendation

GBC AG has begun coverage on Austrian biotech firm Marinomed Biotech AG, issuing a Buy recommendation with a EUR 42.00 price target. This marks a notable increase from the March 26 closing price of EUR 14.20. Marinomed, post-restructuring in 2024, focuses on its Marinosolv® technology, enhancing solubility and bioavailability of active ingredients.

Their development pipeline includes Budesolv, a nasal spray for allergic rhinitis, and Tacrosolv, eye drops for inflammatory diseases. These products address both medical and regulatory demands, positioning Marinomed as a key player for global licensing.

Marinomed will present at the 39th Munich Capital Market Conference on April 2, 2025, showcasing their strategy and potential to institutional investors.